# Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months

> **NCT00649883** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 360 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Trivalent Inactivated vaccines Novartis
- **BIOLOGICAL:** Influenza Trivalent Inactivated vaccines

## Key facts

- **NCT ID:** NCT00649883
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-04
- **Final completion:** 2008-10
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2017-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00649883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00649883, "Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00649883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*